Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxal
AI-powered HER2 quantification provides a refined biomarker for predicting the response to HER2-targeted therapies in BTC, proposing a ≥30% HER2 3+ tumor cell proportion threshold. Our findings highlight the potential of combining anti-HER2 therapy with immune checkpoint inhibitors on the basis of IP profiles.
Authors
- Choong‐kun Lee (ORCID: https://orcid.org/0000-0001-5151-5096)
- Myung Ah Lee (ORCID: https://orcid.org/0000-0002-1204-0574)
- Chiyoon Oum (ORCID: https://orcid.org/0000-0002-4264-7342)
- Hyeon-Su Im (ORCID: https://orcid.org/0000-0002-1393-4246)
- Chan‐Young Ock (ORCID: https://orcid.org/0000-0002-6755-9728)
- Soo Ick Cho (ORCID: https://orcid.org/0000-0003-3414-9869)
- Taekjin Nam
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Min Hwan Kim (ORCID: https://orcid.org/0000-0002-1595-6342)
- Hye Jin Choi (ORCID: https://orcid.org/0000-0001-5917-1400)
- Hong-Sik Kim (ORCID: https://orcid.org/0000-0003-1232-9439)
- Wonkyung Jung (ORCID: https://orcid.org/0009-0006-3520-3432)
Institutions
- Yonsei University (KR)
- CHA University Bundang Medical Center (KR)
- Ulsan University Hospital (KR)
- CHA University (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Chungbuk National University Hospital (KR)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/po-25-00510
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01